Posted by Michael Wonder on 06 Dec 2021
Sapience Therapeutics receives FDA fast track designation for ST101 for the treatment of recurrent glioblastoma multiforme
6 December 2021 - Sapience Therapeutics announced today that the U.S. FDA has granted fast track designation to its lead program investigating ST101 for the treatment of recurrent glioblastoma.
ST101 is currently being evaluated in an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumours, which includes a glioblastoma multiforme expansion cohort.
